Edit Startup: KYAN Technologies

You do not have permission to edit this page, for the following reason:

The action you have requested is limited to users in the group: Users.

Welcome! You're creating or editing a startup page.

If you haven't, we suggest reading our general editing principles first. Also note our position on AI-generated content.

How to use the template

Fill out the form, then add the page content below.

Form

None of the form's fields are strictly mandatory, so skip them if you are uncertain of the values.

Page Content

We strongly suggest using the Visual Editor. To do this:

Saving the page after filling up the form
Click on the "Edit" link on the top right of the newly created page.

Before moving further, please read the following notes on the page template:

Where information is unavailable or unsubstantial, delete sections as necessary
Add sections as necessary
If you substantially adapt from Wikipedia (which is okay), include {{From_Wikipedia}} at the bottom of the page

Logo:	Upload file
Status:
Website (include https://):
Vertical(s):
Technology Readiness Level:	Research (TRL 1-3) Development (TRL 4-6) Deployment (TRL 7-8) Fully Commercialised (TRL 9) Unknown/Not Applicable
Latest Funding:
Founding Year:
Headquarters:
Active In (other countries):
Spun off from:

Page Content
KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development in oncology. ==Technology== KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platform to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types. The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web |title=Translational Biobank |url=https://kyantechnologies.com/translational-biobank/ |access-date=2025-12-20 |website=KYAN Technologies |language=en}}</ref>. ==Traction== KYAN Technologies received Singapore licensing approval for it's clinical laboratory facility in late May 2023<ref>{{Cite web |last=admin |date=2023-05-29 |title=Singapore becomes the first country to approve Optim.AI™, KYAN's Personalized Medicine Solution for cancer patients |url=https://kyantechnologies.com/singapore-becomes-the-first-country-to-approve-optim-ai-kyans-personalized-medicine-solution-for-cancer-patients/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. Their facility is located in [[Temasek Life Science Laboratory]]. Their initial services included laboratory developed tests for lymphoma cases, research for other cancer indications, and development of novel biopharmaceutical assets. In February 2025, the startup announced a collaboration with OncoCare Malaysia to expand the use of KYAN Technologies' testing platform<ref>{{Cite web |last=admin |date=2025-02-05 |title=KYAN Technologies announces collaboration with OncoCare Malaysia |url=https://kyantechnologies.com/kyan-technologies-announces-collaboration-with-oncocare-malaysia/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. In March 2025, KYAN Technologies entered a collaboration with Mayo Clinic Laboratories to validate and provide the startup's testing platform across the United States<ref>{{Cite web |last=admin |date=2025-03-13 |title=Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing |url=https://kyantechnologies.com/mayo-clinic-laboratories-and-kyan-technologies-enter-a-collaboration-to-expand-patients-access-to-cancer-testing/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref>. ==Funding== KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>{{Startup/Funding history}} == References == {{Reflist}}

Summary:

Cancel